Strategic Focus Clinical-stage HIV therapeutic vaccine developer with exclusive HTI immunogen license, positioned to partner with larger pharma companies on cure/eradication strategies and potential combination therapies.

Partnership History Past collaborations with Gilead and ties to HIVACAT indicate openness to industry partnerships and co-development models, suggesting actionable pathways for licensing, joint programs, or sponsored research.

Target Market Niche Specialized HIV vaccine immunogen platform aiming to reeducate the immune system; potential opportunities with large biopharma focused on HIV cure strategies, viral remission, or reduced ART dependence.

Funding/Scale Small team with modest funding but established R&D momentum; leverage for early-stage pilot projects, contracted research, or milestone-based collaborations to accelerate development without heavy upfront risk.

Global Reach Barcelona-based with international press coverage; potential to leverage EU biotech networks and public-private partnerships for grant-funded programs, clinical trial support, and regional regulatory navigation.